Clinical Trials
130 trialsSTARTRK-2
Hoffmann-La Roche
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Massachusetts General Hospital
EPIBREAST
UNICANCER
Resimmune®
Virogen Biotechnology Inc.
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Massachusetts General Hospital
NeoRelapse
University of Utah
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
M.D. Anderson Cancer Center
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
National Cancer Institute (NCI)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
Treating Patients With Melanoma and ALK Alterations With Ensartinib
Memorial Sloan Kettering Cancer Center
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
National Cancer Institute (NCI)
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Canbiome2
Canadian Cancer Trials Group
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
LANCE
Jules Bordet Institute
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Memorial Sloan Kettering Cancer Center
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
Thomas Jefferson University
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
University of Michigan Rogel Cancer Center
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma.
SkinJect, Inc.
INFLECTION-003
Primmune Therapeutics, Inc.
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Dinaciclib in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TELLOMAK
Innate Pharma
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NAVIGATE
Bayer
Photopheresis in Early-stage Mycosis Fungoides
Columbia University